Elizabeth Jaffee
#68,153
Most Influential Person Now
American oncologist
Elizabeth Jaffee's AcademicInfluence.com Rankings
Elizabeth Jaffeemedical Degrees
Medical
#771
World Rank
#1013
Historical Rank
Oncology
#35
World Rank
#37
Historical Rank
Download Badge
Medical
Elizabeth Jaffee's Degrees
- Doctorate Medicine University of Pennsylvania
Why Is Elizabeth Jaffee Influential?
(Suggest an Edit or Addition)According to Wikipedia, Elizabeth M. Jaffee is an American oncologist specializing in pancreatic cancer and immunotherapy. Education Jaffee completed her undergraduate degree at Brandeis University in 1981 and earned her MD from New York Medical College in 1985. Following medical school, she did her residency at Presbyterian-University Hospital in Pittsburgh, Pennsylvania. After residency she received a position as a research fellow at the University of Pittsburgh.
Elizabeth Jaffee's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses (2008) (3758)
- Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. (1993) (2825)
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition. (2017) (1868)
- Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. (1994) (1261)
- Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. (2000) (1220)
- Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene (2009) (788)
- Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. (2019) (709)
- Mechanisms of immune evasion by tumors. (2006) (646)
- Targeting neoantigens to augment antitumour immunity (2017) (621)
- Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. (2001) (567)
- Cancer Vaccines (1997) (546)
- Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). (2001) (545)
- Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. (2018) (538)
- Compromised HOXA5 function can limit p53 expression in human breast tumours (2000) (507)
- Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. (2001) (479)
- Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. (2015) (470)
- Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. (2003) (466)
- Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer (2013) (466)
- Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. (1997) (453)
- Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response (2005) (424)
- The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. (1996) (395)
- Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation (2014) (377)
- The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities (2020) (376)
- Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. (2017) (364)
- Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma (2016) (354)
- The determinants of tumour immunogenicity (2012) (339)
- Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. (2001) (332)
- PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors (2015) (332)
- SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer (2009) (329)
- Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. (2008) (328)
- Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients (2004) (323)
- Major histocompatibility complex class II‐restricted presentation of a cytosolic antigen by autophagy (2003) (323)
- Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. (2000) (308)
- Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. (2010) (303)
- Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation (2008) (302)
- Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. (2014) (300)
- A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction (2011) (298)
- Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells (2015) (287)
- PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. (2019) (282)
- PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. (2016) (278)
- Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. (1998) (255)
- Focus on pancreas cancer. (2002) (247)
- HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. (2000) (246)
- Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. (2013) (243)
- Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) (2018) (241)
- Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. (2012) (222)
- Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo (2003) (222)
- Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. (2009) (214)
- Demonstration of a rational strategy for human prostate cancer gene therapy. (1994) (214)
- Mesothelin Immunotherapy for Cancer: Ready for Prime Time? (2016) (211)
- A reassessment of the role of B7-1 expression in tumor rejection (1995) (197)
- A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based Mechanism (2007) (194)
- Immunotherapy for pancreatic cancer — science driving clinical progress (2005) (193)
- Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. (2017) (182)
- Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. (1993) (178)
- Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. (2007) (176)
- Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. (2005) (171)
- The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. (2001) (169)
- Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice (2005) (167)
- Use of tumour-responsive T cells as cancer treatment (2009) (164)
- Tyrosine 23 Phosphorylation-Dependent Cell-Surface Localization of Annexin A2 Is Required for Invasion and Metastases of Pancreatic Cancer (2011) (163)
- Human mononuclear phagocyte antiprotozoal mechanisms: oxygen-dependent vs oxygen-independent activity against intracellular Toxoplasma gondii. (1985) (158)
- T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. (2018) (155)
- Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited. (2020) (154)
- Defining the critical hurdles in cancer immunotherapy (2011) (152)
- Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer. (2016) (150)
- Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors (2017) (147)
- Current progress in immunotherapy for pancreatic cancer. (2016) (146)
- Consistent chromosome abnormalities in adenocarcinoma of the pancreas. (1995) (135)
- High efficiency gene transfer into primary human tumor explants without cell selection. (1993) (132)
- Emerging strategies for combination checkpoint modulators in cancer immunotherapy (2018) (130)
- Cellular Vaccine Approaches (2010) (127)
- Genetic mutations associated with cigarette smoking in pancreatic cancer. (2009) (126)
- Future cancer research priorities in the USA: a Lancet Oncology Commission. (2017) (125)
- A white paper: the product of a pancreas cancer think tank. (2001) (124)
- Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. (2010) (124)
- The immune microenvironment of breast ductal carcinoma in situ (2016) (123)
- Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival (2019) (122)
- A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. (2014) (121)
- Whole cell vaccines--past progress and future strategies. (2012) (119)
- Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study) (2019) (116)
- Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs (2018) (116)
- Fusion to Listeriolysin O and Delivery by Listeria monocytogenes Enhances the Immunogenicity of HER-2/neu and Reveals Subdominant Epitopes in the FVB/N Mouse1 (2005) (114)
- Strategies for Increasing Pancreatic Tumor Immunogenicity (2017) (114)
- Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future. (2020) (112)
- Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. (1998) (112)
- Allergies and the Risk of Pancreatic Cancer: A Meta-analysis with Review of Epidemiology and Biological Mechanisms (2005) (109)
- A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice (2017) (104)
- HER-2/neu-Specific Monoclonal Antibodies Collaborate with HER-2/neu-Targeted Granulocyte Macrophage Colony-Stimulating Factor Secreting Whole Cell Vaccination to Augment CD8+ T Cell Effector Function and Tumor-Free Survival in Her-2/neu-Transgenic Mice1 (2003) (102)
- Targeting neoantigens to augment antitumour immunity (2017) (101)
- Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer. (2018) (101)
- A preclinical murine model of hepatic metastases. (2014) (101)
- OX40 Costimulation Synergizes with GM-CSF Whole-Cell Vaccination to Overcome Established CD8+ T Cell Tolerance to an Endogenous Tumor Antigen1 (2006) (99)
- Characterization of the Immune Microenvironment in Hepatocellular Carcinoma (2017) (95)
- A multimodality test to guide the management of patients with a pancreatic cyst (2019) (94)
- Cancer immunologists and cancer biologists: why we didn't talk then but need to now. (2007) (94)
- Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. (2008) (88)
- Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. (1995) (87)
- Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. (2005) (87)
- Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. (1998) (87)
- Chemotherapy: friend or foe to cancer vaccines? (2001) (85)
- De novo DNA methylation by DNA methyltransferase 3a controls early effector CD8+ T-cell fate decisions following activation (2016) (85)
- Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. (2007) (82)
- Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer (2015) (80)
- A Phase I Clinical Trial of Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected with the GM-CSF Gene for the Treatment of Pancreatic Adenocarcinoma. The Johns Hopkins Oncology Center, Baltimore, Maryland (1998) (79)
- Identification and Characterization of the Immunodominant Rat HER-2/neu MHC Class I Epitope Presented by Spontaneous Mammary Tumors from HER-2/neu-Transgenic Mice1 (2003) (78)
- Human Cancer Cell Membrane-Coated Biomimetic Nanoparticles Reduce Fibroblast-Mediated Invasion and Metastasis and Induce T-Cells. (2019) (77)
- Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade (2021) (76)
- Cancer-Associated Fibroblasts in Pancreatic Cancer Are Reprogrammed by Tumor-Induced Alterations in Genomic DNA Methylation. (2016) (76)
- Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. (2019) (75)
- Increased Expression of DNA Repair Genes in Invasive Human Pancreatic Cancer Cells (2011) (75)
- Nanoparticle interactions with immune cells dominate tumor retention and induce T cell–mediated tumor suppression in models of breast cancer (2020) (75)
- A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell–Mediated Anticancer Activity (2019) (74)
- Ductal access for prevention and therapy of mammary tumors. (2006) (74)
- Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. (1996) (72)
- Heterogeneous Stromal Signaling within the Tumor Microenvironment Controls the Metastasis of Pancreatic Cancer. (2017) (71)
- Effective Depletion of Regulatory T Cells Allows the Recruitment of Mesothelin‐Specific CD8+ T Cells to the Antitumor Immune Response Against a Mesothelin‐Expressing Mouse Pancreatic Adenocarcinoma (2008) (70)
- Large Cell Neuroendocrine Carcinoma of the Head and Neck: A Clinicopathologic Series of 10 Cases With an Emphasis on HPV Status (2016) (70)
- Bone marrow-derived cells present MHC class I-restricted tumour antigens in priming of antitumour immune responses. (1994) (67)
- A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF–Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer (2014) (67)
- Why is pancreatic cancer so deadly? The pathologist's view (2019) (65)
- Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines. (1992) (65)
- OX40 costimulation can abrogate Foxp3+ regulatory T cell‐mediated suppression of antitumor immunity (2009) (65)
- The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy. (2015) (64)
- Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived (2002) (64)
- Axon Guidance Molecules Promote Perineural Invasion and Metastasis of Orthotopic Pancreatic Tumors in Mice. (2019) (64)
- Axon Guidance Molecules Promote Perineural Invasion and Metastasis of Orthotopic Pancreatic Tumors in Mice. (2019) (64)
- Peptide-based PET quantifies target engagement of PD-L1 therapeutics (2019) (64)
- Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade (2019) (63)
- Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade (2019) (63)
- Mapping patterns of local recurrence after pancreaticoduodenectomy for pancreatic adenocarcinoma: a new approach to adjuvant radiation field design. (2013) (62)
- TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner (2015) (59)
- Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. (1996) (58)
- Transcriptional profiling identifies novel regulators of macrophage polarization (2018) (58)
- Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity (2021) (58)
- Murine tumor antigens: is it worth the search? (1996) (57)
- Simplified high-sensitivity sequencing of a major histocompatibility complex class I-associated immunoreactive peptide using matrix-assisted laser desorption/ionization mass spectrometry. (1995) (57)
- Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells. (2003) (57)
- Intraductal Papillary Mucinous Neoplasms Arise from Multiple Independent Clones, Each With Distinct Mutations. (2019) (57)
- Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer (2017) (56)
- Vaccine therapy for pancreatic cancer (2013) (56)
- A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. (1998) (54)
- Development of a novel preclinical pancreatic cancer research model: bioluminescence image-guided focal irradiation and tumor monitoring of orthotopic xenografts. (2012) (54)
- Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer (2020) (54)
- Leveraging premalignant biology for immune-based cancer prevention (2016) (52)
- Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis (2020) (51)
- Cancer cells educate natural killer cells to a metastasis-promoting cell state (2020) (50)
- A U.S. “Cancer Moonshot” to accelerate cancer research (2016) (49)
- Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue. (2013) (49)
- Pancreatic cancer. (2002) (49)
- Humoral and cellular immune responses: independent forces or collaborators in the fight against cancer? (2001) (49)
- Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. (2021) (48)
- How much longer will tumour cells fool the immune system? (2000) (48)
- Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma (2019) (47)
- Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines. (1997) (47)
- Trafficking of High Avidity HER-2/neu-Specific T Cells into HER-2/neu-Expressing Tumors after Depletion of Effector/Memory-Like Regulatory T Cells (2012) (46)
- A Blueprint to Advance Colorectal Cancer Immunotherapies (2017) (46)
- Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). (2017) (46)
- Cancer Vaccines: An Old Idea Comes of Age (2003) (46)
- Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine. (2005) (46)
- Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. (2012) (46)
- PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition (2014) (45)
- Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer (2019) (44)
- Cancer Immunotherapy : Immune Suppression and Tumor Growth (2007) (42)
- Nonviral Oncogenic Antigens and the Inflammatory Signals Driving Early Cancer Development as Targets for Cancer Immunoprevention (2015) (42)
- Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. (2000) (41)
- A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer (2020) (41)
- Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice. (2007) (41)
- Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors (2019) (41)
- Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies (2019) (41)
- A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer (2020) (41)
- Single‐cell sequencing defines genetic heterogeneity in pancreatic cancer precursor lesions (2019) (40)
- A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. (2004) (39)
- Genomic characterization of malignant progression in neoplastic pancreatic cysts (2020) (39)
- Immune Therapy in GI Malignancies: A Review. (2015) (38)
- Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy (2014) (38)
- From bench to bedside: single-cell analysis for cancer immunotherapy. (2021) (38)
- The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures (2020) (37)
- Prevalence of Germline Mutations Associated With Cancer Risk in Patients With Intraductal Papillary Mucinous Neoplasms. (2019) (36)
- Vaccines for pancreatic cancer. (2012) (35)
- Cytogenetic characterization and gene expression profiling in the rat reflux-induced esophageal tumor model. (2007) (35)
- Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer (2018) (35)
- Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer (2020) (35)
- Molecular cytogenetic characterization of pancreas cancer cell lines reveals high complexity chromosomal alterations (2007) (35)
- A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer (2019) (34)
- Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. (1995) (34)
- A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer (2019) (34)
- Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology (2005) (33)
- Three-dimensional visualization of cleared human pancreas cancer reveals that sustained epithelial-to-mesenchymal transition is not required for venous invasion (2019) (33)
- Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer (2021) (33)
- Mesothelin-specific CD 8 T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients (2004) (33)
- Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1 (2019) (33)
- Current Status of Immunotherapies for Treating Pancreatic Cancer (2019) (32)
- Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival (2015) (32)
- Low Total Lymphocyte Count Is Associated with Poor Survival in Patients with Resected Pancreatic Adenocarcinoma Receiving a GM-CSF Secreting Pancreatic Tumor Vaccine (2013) (32)
- Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome (2020) (32)
- A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results. (2014) (31)
- Immunotherapy of Cancer (1999) (30)
- Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective (2017) (30)
- In situ characterization of the 3D microanatomy of the pancreas and pancreatic cancer at single cell resolution (2020) (30)
- Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast Cancer (2020) (30)
- Pancreatic Cancer: Pathogenesis, Screening, Diagnosis and Treatment. (2022) (29)
- Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma (2020) (29)
- Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy (2019) (29)
- Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy (2019) (29)
- Stromal changes in the aged lung induce an emergence from melanoma dormancy (2020) (29)
- A safety and efficacy trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene in combination with adjuvant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas (2007) (28)
- Annexin A2 is a new antigenic target for pancreatic cancer immunotherapy (2012) (28)
- Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer. (2017) (28)
- Immunobiology of Radiotherapy: New Paradigms (2014) (28)
- Intracranial Paracrine Interleukin-2 Therapy Stimulates Prolonged Antitumor Immunity That Extends Outside the Central Nervous System (2000) (28)
- Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis (2020) (28)
- PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast (2017) (28)
- Alteration of Cellular and Humoral Immunity by Mutant p53 Protein and Processed Mutant Peptide in Head and Neck Cancer (2007) (28)
- Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation. (2012) (27)
- Periadventitial dissection of the superior mesenteric artery for locally advanced pancreatic cancer: Surgical planning with the "halo sign" and "string sign". (2020) (27)
- Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice (2013) (27)
- A Safety and Feasibility Study of an Allogeneic Colon Cancer Cell Vaccine Administered with a Granulocyte–Macrophage Colony Stimulating Factor–Producing Bystander Cell Line in Patients with Metastatic Colorectal Cancer (2014) (26)
- Cancer vaccines (2000) (26)
- Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors (2020) (26)
- An empirical antigen selection method identifies neoantigens that either elicit broad anti-tumor T cell responses or drive tumor growth. (2021) (26)
- Peptidases released by necrotic cells control CD8+ T cell cross-priming. (2013) (26)
- Immunotherapy transforms cancer treatment. (2018) (25)
- CD8+Foxp3+ tumor infiltrating lymphocytes accumulate in the context of an effective anti‐tumor response (2011) (25)
- Genetically Engineered Tumor Cell Vaccine in a Head and Neck Cancer Model (2003) (24)
- Immunologic approaches to the management of pancreatic cancer. (2001) (23)
- Tumor‐specific CD4+ T cells from a patient with renal cell carcinoma recognize diverse shared antigens (2005) (23)
- Neoadjuvant nivolumab plus concurrent chemoradiation in stage II/III esophageal/gastroesophageal junction cancer. (2019) (23)
- Multiregion whole-exome sequencing of intraductal papillary mucinous neoplasms reveals frequent somatic KLF4 mutations predominantly in low-grade regions (2020) (23)
- Molecular characterization of organoids derived from pancreatic intraductal papillary mucinous neoplasms (2020) (22)
- Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy (2020) (22)
- Toward a breast cancer vaccine: work in progress. (2003) (22)
- Targeting Mechanoresponsive Proteins in Pancreatic Cancer: 4-Hydroxyacetophenone Blocks Dissemination and Invasion by Activating MYH14 (2019) (22)
- Synergistic Effects of A1896, T1653 and T1762/A1764 Mutations in Genotype C2 Hepatitis B Virus on Development of Hepatocellular Carcinoma (2013) (21)
- Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment (2017) (21)
- Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer (2016) (20)
- Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer (2016) (20)
- Cancer Immunoprevention—The Next Frontier (2014) (20)
- Nondominant CD8 T Cells Are Active Players in the Vaccine-Induced Antitumor Immune Response (2011) (20)
- Effects of B cell-activating factor on tumor immunity. (2020) (20)
- MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity (2019) (19)
- Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine. (2013) (19)
- Augmenting the potency of breast cancer vaccines: combined modality immunotherapy. (2004) (19)
- Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR) (2015) (19)
- Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma (2020) (18)
- Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma (2020) (18)
- Pancreatic Neoplasms With Acinar Differentiation: A Review of Pathologic and Molecular Features. (2019) (18)
- Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas (2020) (18)
- Prophylactic Vaccines for Nonviral Cancers (2018) (17)
- Immune Modulation Therapy and Imaging: Workshop Report (2017) (17)
- Differential variation analysis enables detection of tumor heterogeneity using single-cell RNA-sequencing data. (2019) (17)
- Stromal Annexin A2 expression is predictive of decreased survival in pancreatic cancer (2017) (17)
- Apoptosis-Regulated Low-Avidity Cancer-Specific CD8+ T Cells Can Be Rescued to Eliminate HER2/neu–Expressing Tumors by Costimulatory Agonists in Tolerized Mice (2014) (17)
- The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go (2020) (17)
- Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma (2019) (17)
- A feasibility study of combination therapy with trastuzumab (T), cyclophosphamide (CY), and an allogeneic GM-CSF-secreting breast tumor vaccine for the treatment of HER2+ metastatic breast cancer. (2011) (16)
- Cytokine gene-modified cell-based cancer vaccines. (2002) (16)
- Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways (2021) (16)
- An Immunodominant MHC Class II-Restricted Tumor Antigen Is Conformation Dependent and Binds to the Endoplasmic Reticulum Chaperone, Calreticulin1 (2001) (16)
- Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways (2021) (16)
- Special Conference on Tumor Immunology and Immunotherapy: A New Chapter (2015) (16)
- Anti–CTLA‐4 synergizes with dendritic cell–targeted vaccine to promote IL‐3–dependent CD4+ effector T cell infiltration into murine pancreatic tumors (2019) (16)
- A "Clearer" View of Pancreatic Pathology: A Review of Tissue Clearing and Advanced Microscopy Techniques. (2019) (15)
- Harnessing Immune Responses in the Tumor Microenvironment: All Signals Needed (2013) (15)
- Rapid characterization of candidate biomarkers for pancreatic cancer using cell microarrays (CMAs). (2012) (15)
- To Live or Not to Live–THAT Depends on GAGE? (2002) (15)
- Systemic inhibition of PTPN22 augments anticancer immunity. (2021) (15)
- Targeting mechanoresponsive proteins in pancreatic cancer: 4-hydroxyacetophenone blocks dissemination and invasion by activating MYH14. (2019) (15)
- Vaccine Impedes the Development of Reflux-Induced Esophageal Cancer in a Surgical Rat Model: Efficacy of the Vaccine in a Pre-Barrett’s Esophagus Setting (2007) (14)
- OX 40 Costimulation Synergizes with GM-CSF Whole-Cell Vaccination to Overcome Established CD 8 T Cell Tolerance to an Endogenous Tumor Antigen 1 (2005) (14)
- Role of in silico structural modeling in predicting immunogenic neoepitopes for cancer vaccine development (2020) (14)
- Targeting the right regulatory T-cell population for tumor immunotherapy (2012) (14)
- Spatial Distribution of Tumor Vaccine Improves Efficacy (2003) (13)
- Cancer vaccines in combination with multimodality therapy. (2005) (13)
- Effects of Genomic Changes in Hepatitis B Virus on Postoperative Recurrence and Survival in Patients with Hepatocellular Carcinoma (2013) (12)
- Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR). (2016) (12)
- A roadmap for the next decade in cancer research (2020) (12)
- Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC). (2021) (12)
- Breast Cancer Research and Treatment 2001 Reviewers (2004) (12)
- Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy (2020) (12)
- Immune cells track hard-to-target brain tumours (2018) (12)
- Use and benefits of a Web site for pancreatic cancer. (1998) (11)
- Evaluating the impact of age on immune checkpoint therapy biomarkers (2021) (11)
- Cytokine modified tumor vaccines. (2002) (11)
- Gene therapy: its potential applications in the treatment of renal-cell carcinoma. (1995) (11)
- Shared genetic and epigenetic changes link aging and cancer. (2022) (11)
- Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide (2020) (10)
- Continuing Undergraduate Pathology Medical Education in the Coronavirus Disease 2019 (COVID-19) Global Pandemic: The Johns Hopkins Virtual Surgical Pathology Clinical Elective. (2021) (10)
- Messenger RNA vaccines for cancer immunotherapy: progress promotes promise (2022) (10)
- Multi-panel mass cytometry reveals anti-PD1 therapy-mediated B and T cell compartment remodeling in tumor-draining lymph nodes. (2019) (10)
- Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances. (2013) (10)
- Potential role of tumor vaccines in GI malignancies. (2000) (9)
- Immunotherapy in preneoplastic disease: targeting early procarcinogenic inflammatory changes that lead to immune suppression and tumor tolerance (2013) (9)
- CODA: quantitative 3D reconstruction of large tissues at cellular resolution (2022) (9)
- Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumors (2020) (9)
- Inhibition of miR-21 Regulates Mutant KRAS Effector Pathways and Intercepts Pancreatic Ductal Adenocarcinoma Development (2020) (9)
- Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017 (2020) (9)
- Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer (2017) (9)
- Phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer: Clinical update on long term survival and biomarker correlates to overall survival. (2015) (9)
- Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017 (2020) (9)
- Women in oncology: progress, challenges, and keys to success. (2013) (9)
- Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844) (2021) (9)
- Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics (2021) (8)
- A framework for fibrolamellar carcinoma research and clinical trials (2022) (8)
- Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR (2021) (8)
- Preliminary Results of a Pilot Study Evaluating An Allogeneic GM-CSF Pancreatic Tumor Cell Vaccine (GVAX) and Cytoxan (Cy) With Stereotactic Body Radiation Therapy (SBRT) and Folfirinox (FFX) in Patients With Resected Pancreatic Adenocarcinoma (2015) (8)
- Genomic change in hepatitis B virus associated with development of hepatocellular carcinoma. (2016) (8)
- Interim safety and efficacy analysis of a phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer. (2013) (7)
- Hedgehog signaling stimulates Tenascin C to promote invasion of pancreatic ductal adenocarcinoma cells through Annexin A2 (2017) (7)
- A global live cell barcoding approach for multiplexed mass cytometry profiling of mouse tumors (2021) (7)
- NF-κB p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma (2020) (7)
- A phase 2, multicenter study of FOLFIRINOX followed by ipilimumab in combination with allogeneic GM-CSF transfected pancreatic tumor vaccine in the treatment of metastatic pancreatic cancer. (2014) (7)
- Macrophage-Targeting by CSF1/1R Blockade in Pancreatic Cancers (2021) (7)
- A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint (2021) (7)
- Disrupting a converging metabolic target turns up the immunologic-heat in pancreatic tumors. (2019) (7)
- A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint (2021) (7)
- Immunotherapy and Cancer Therapeutics: Why Partner? (2007) (7)
- Precision medicine in pancreatic cancer: Patient derived organoid pharmacotyping is a predictive biomarker of clinical treatment response. (2022) (7)
- Cancer Moonshot 2.0. (2021) (7)
- Intraductal Pancreatic Cancer is Less Responsive Than Cancer in the Stroma to Neoadjuvant Chemotherapy (2020) (6)
- Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances (2013) (6)
- Phase 1b/2 study of nivolumab in combination with an anti–IL-8 monoclonal antibody, BMS-986253, in a biomarker-enriched population of patients with advanced cancer. (2018) (6)
- Defining a minimum number of examined lymph nodes improves the prognostic value of lymphadenectomy in pancreas ductal adenocarcinoma. (2020) (6)
- The Impact of Clinical and Pathological Features on Intraductal Papillary Mucinous Neoplasm Recurrence After Surgical Resection (2020) (6)
- A novel mechanism of natural killer cell response to anti-CTLA-4 therapy identified by integrative analysis of mouse and human tumors (2020) (6)
- Phase II study of GM-CSF secreting allogeneic pancreatic cancer vaccine (GVAX) with PD-1 blockade antibody and stereotactic body radiation therapy (SBRT) for locally advanced pancreas cancer (LAPC). (2017) (6)
- How Did We Get a COVID-19 Vaccine in Less Than 1 Year? (2021) (6)
- Metastatic breast cancer simulating well-differentiated neuroendocrine neoplasms of visceral organs. (2018) (6)
- Entinostat decreases immune suppression to promote anti-tumor responses in a HER2+ breast tumor microenvironment. (2022) (5)
- Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer (2020) (5)
- Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer (2011) (5)
- Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma. (2018) (5)
- Carcinoma of the Pancreas (1983) (5)
- Vaccine Impedes the Development of Reflux-induced Esophageal Cancer in a Surgical Rat Model: Efficacy of the Vaccine in a Post-Barrett’s Esophagus Setting (2008) (5)
- Profiling of syngeneic mouse HCC tumor models as a framework to understand anti–PD‐1 sensitive tumor microenvironments (2022) (5)
- Phase Ib study of ipilimumab alone or in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene (vaccine) in pancreatic cancer. (2012) (5)
- Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition (2013) (5)
- Effect of inhibition of poly-(ADP ribose) polymerase on gemcitabine and radiation-induced cytotoxicity of pancreatic cancer cells. (2011) (5)
- MyD 88-Dependent SHIP 1 Regulates Proinflammatory Signaling Pathways in Dendritic Cells after Monophosphoryl Lipid A Stimulation of TLR 4 (2011) (5)
- A phase II study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair–proficient (MMR-p) advanced colorectal cancer. (2019) (5)
- Epigenetic priming prior to pembrolizumab in mismatch repair-proficient advanced colorectal cancer. (2019) (4)
- An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma (2020) (4)
- Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy (2022) (4)
- Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist Therapy (2021) (4)
- Relationship between lymphopenia and objective response rate with programmed death-1 (PD-1) inhibitor therapy: A single-center retrospective analysis. (2017) (4)
- Live-attenuated L. monocytogenes encoding mesothelin for immunotherapy of patients with pancreas and ovarian cancers (2007) (4)
- Equity and diversity in academic medicine: a perspective from the JCI editors. (2019) (4)
- Harnessing the adaptive potential of mechanoresponsive proteins to overwhelm pancreatic cancer dissemination and invasion (2017) (4)
- Clinical experience with live-attenuated, double-deleted (LADD) listeria monocytogenes targeting mesothelin-expressing tumors (2013) (4)
- Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine. (2005) (4)
- Can We Predict Mutant Neoepitopes in Human Cancers for Patient-Specific Vaccine Therapy? (2014) (4)
- Inflammatory Signaling and Fibroblast-Cancer Cell Interactions Transfer from a Harmonized Human Single-cell RNA Sequencing Atlas of Pancreatic Ductal Adenocarcinoma to Organoid Co-Culture (2022) (3)
- Relationship of lymphocyte and eosinophil counts and immune-related adverse events in recipients of programmed death-1 (PD-1) inhibitor therapy: A single-center retrospective analysis. (2017) (3)
- Abstract CT207: Feasibility of neoadjuvant cabozantinib plus nivolumab followed by definitive resection for patients with locally advanced hepatocellular carcinoma: A Phase Ib trial (NCT03299946) (2019) (3)
- Generation and characterization of a cell line from an intraductal tubulopapillary neoplasm of the pancreas (2020) (3)
- 146: Adjuvant Chemoradiation for Adenocarcinoma of the Pancreas: The Johns Hopkins Experience (2006) (3)
- Pancreatic Nerve Sheath Tumors: a Single Institutional Series and Systematic Review of the Literature (2019) (3)
- Spatial transcriptomics of FFPE pancreatic intraepithelial neoplasias reveals cellular and molecular alterations of progression to pancreatic ductal carcinoma (2022) (3)
- A phase I/II study of PI3Kinase inhibition with copanlisib combined with the anti-PD-1 antibody nivolumab in relapsed/refractory solid tumors with expansions in MSS colorectal cancer. (2020) (3)
- Abstract 3026: Role of AnnexinA2, Sema3D and PlexinD1 in mediating perineural invasion as a mechanism of metastasis in pancreatic ductal adenocarcinoma (2018) (3)
- Progress Toward Cancer Vaccines (2000) (3)
- Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognostic Biomarkers (2022) (3)
- Phase II study of nivolumab and relatlimab in advanced mismatch repair deficient (dMMR) cancers resistant to prior PD-(L)1 inhibition. (2020) (3)
- Advances in Brief The Collaboration of Both Humoral and Cellular HER-2 / neu-targeted Immune Responses Is Required for the Complete Eradication of HER-2 / neu-expressing Tumors 1 (2001) (3)
- Circulating tumor DNA (ctDNA) as a prognostic marker for recurrence in resected pancreas cancer. (2015) (3)
- A phase I study of MORab-009, a monoclonal antibody against mesothelin, in mesothelioma, pancreatic and ovarian cancer (2008) (3)
- Correction: Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. (2019) (3)
- Adaptive immune resistance in gastro-esophageal cancer: Correlating tumoral/stromal PDL1 expression with CD8+ cell count. (2015) (3)
- Pancreatic cancer pathology viewed in the light of evolution (2021) (3)
- Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer. (2014) (3)
- Increasing doses of cyclophosphamide suppress antigen-specific T helper-dependent immunity induced by a GM-CSF-secreting breast tumor vaccine (2008) (3)
- Forecasting cancer: from precision to predictive medicine. (2021) (3)
- Abstract 320: Inhibition of adenosine A2A receptor (A2AR) by CPI-444 enhances CD8+ T cell killing of a HER-2/neu expressing murine tumor (2016) (3)
- Modified STING-activating cyclic dinucleotide derivatives significantly enhance the anti-tumor activity of therapeutic vaccines (2013) (3)
- Tumor mutational burden (TMB) and response rates to immune checkpoint inhibitors (ICIs) targeting PD-1, CTLA-4, and combination. (2019) (3)
- Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection (2021) (3)
- Abstract OT3-02-03: IMMUNe mOdulation in early stage estrogen receptor positive breast cancer treated with neoADjuvant Avelumab, Palbociclib, and Tamoxifen: The ImmunoADAPT study (NCT03573648) (2019) (3)
- Expression variation analysis for tumor heterogeneity in single-cell RNA-sequencing data (2018) (2)
- Fusion Protein of Mutant B7-DC and Fc Enhances the Antitumor Immune Effect of GM-CSF-secreting Whole-cell Vaccine (2014) (2)
- Abstract 5579: Strategic inhibition of adenosine A2A receptor (A2AR) by CPI-444 improves CD8+:Treg ratios and enhances T-cell killing of a HER-2/neu expressing murine tumor (2017) (2)
- Report on the Third FDA–AACR Oncology Dose-Finding Workshop (2017) (2)
- Clinical and immune characteristics of rapid dropout and long-term survival in a phase II safety and efficacy study of combination CRS-207/GVAX immunotherapy in pancreatic cancer. (2016) (2)
- Immune checkpoint inhibitors 2 . 1 CTLA-4 (2016) (2)
- Analysis of Population Differences in Digital Conversations About Cancer Clinical Trials: Advanced Data Mining and Extraction Study (2020) (2)
- Sequential treatment with a listeria-based vaccine and PD-1 blockade antibody improves survival in a murine model of pancreatic ductal adenocarcinoma (2016) (2)
- Aging interacts with tumor biology to produce major changes in the immune tumor microenvironment (2020) (2)
- Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy. (2016) (2)
- Biphenotypic Differentiation of Pancreatic Cancer in 3-Dimensional Culture. (2019) (2)
- Vaccine therapy and immunotherapy for pancreatic cancer (2018) (2)
- Abstract 611: PD-1-based combination immunotherapy reinvigorates CD8+T cells in metastatic pancreatic cancer patients with improved survival (2018) (2)
- PanIN and CAF Transitions in Pancreatic Carcinogenesis Revealed with Spatial Data Integration (2022) (2)
- A multivariate model for identifying risk of early death after Pancreaticoduodenectomy(PDD) and adjuvant therapy for periampullary Adenocarcinoma(PA): importance for understanding post treatment outcomes (2002) (2)
- Abstract 4936: Combination CD40 agonist and PD-1 antagonist antibody therapy enhances vaccine induced T cell responses in non-immunogenic cancers (2017) (2)
- Pancreatic cancer: Next-generation algorithms for neoantigen selection (2018) (2)
- Pathology of intraductal papillary mucinous neoplasms (2021) (2)
- Engineered bispecific antibodies targeting the interleukin-6 and -8 receptors potently inhibit cancer cell migration and tumor metastasis. (2022) (2)
- Subdominant Epitopes in the FVB/N Mouse Immunogenicity of HER-2/neu and Reveals Enhances the Listeria monocytogenes Fusion to Listeriolysin O and Delivery by (2005) (2)
- A Phase IIb, randomized, multicenter study of the efficacy of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously-treated metastatic pancreatic adenocarcinoma (eclipse study) (2014) (1)
- Immunotherapy and Cancer Therapeutics: A Rich Partnership (2013) (1)
- Abstract 5716: miR-21 inhibition regulates mutant KRAS effector pathways and intercepts development of pancreatic ductal adenocarcinoma (2020) (1)
- Abstract IA09: A phase II trial to promote recovery from COVID-19 with endocrine therapy (2020) (1)
- Delivery of cytokines by microencapsulated transduced cells (1994) (1)
- Patient retention and costs associated with a pancreatic multidisciplinary clinic. (2012) (1)
- AVascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-BasedMechanism (2007) (1)
- Uncovering the spatial landscape of molecular interactions within the tumor microenvironment through latent spaces (2022) (1)
- Targeting Sema3D in pancreatic cancer: A novel therapeutic strategy. (2015) (1)
- Correction: Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer (2016) (1)
- 1669P Monitoring immune checkpoint inhibition in advanced solid tumors using genome-wide cfDNA fragmentomes (2022) (1)
- P028) Patient Retention After Initial Consultation Results in Extended Survival in Pancreatic Cancer (2017) (1)
- 964MO Entinostat, nivolumab and ipilimumab in advanced HER2-negative breast cancer (ETCTN-9844) (2021) (1)
- Abstract 3102A: Analysis of spatial relationships between infiltrating immune cells within the tumor microenvironment following combinatorial immunotherapy (2019) (1)
- GM-CSF microspheres in cancer immunotherapy - A mechanistic study of the vaccine site (1996) (1)
- Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). (2022) (1)
- 812 Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer (2020) (1)
- Abstract PR9: Granulocyte macrophage colony stimulating factor (GM-CSF) pancreas tumor vaccine in combination with blockade of PD-1 in a preclinical model of pancreatic cancer. (2013) (1)
- 378 SYNERGISTIC EFFECTS OF A1896, T1653 AND T1762/A1764 MUTATIONS IN GENOTYPE C2 HEPATITIS B VIRUS GENOME ON THE OCCURRENCE OF HEPATOCELLULAR CARCINOMA (2011) (1)
- AACR Calls on Congress to Take Immediate Action Against COVID-19 and Protect Patients with Cancer During the Pandemic. (2020) (1)
- Inhibition of the EGFR and hedgehog signaling pathways demonstrate potent growth inhibition in an animal model of esophageal carcinogenesis (2004) (1)
- Abstract 167: Semaphorin3D signaling in the invasion and metastasis of pancreatic ductal adenocarcinoma (2019) (1)
- TH17 cells and early pancreatic tumorigenesis. (2013) (1)
- Multiomics Empowers Predictive Pancreatic Cancer Immunotherapy. (2023) (1)
- The Diagnostic Challenge of Evaluating Small Biopsies from the Pancreatobiliary System. (2022) (1)
- Abstract 3102A: Analysis of spatial relationships between infiltrating immune cells within the tumor microenvironment following combinatorial immunotherapy (2019) (1)
- Evaluating the impact of age on immune checkpoint therapy biomarkers. (2021) (1)
- A phase II trial of PD-1 inhibition with INCMGA00012 in patients with previously treated unresectable or metastatic adenosquamous pancreatic cancer. (2020) (1)
- 1124 A MULTI-MODALITY TEST TO GUIDE THE MANAGEMENT OF PATIENTS WITH PANCREATIC CYSTS (2019) (1)
- Abstract 1682: Imaging mass cytometry reveals key spatial features among immune cells in hepatocellular carcinomas treated with neoadjuvant cabozantinib and nivolumab (2021) (1)
- 812 Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer (2020) (1)
- Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials (2022) (1)
- HMGA1 induces FGF19 to drive pancreatic carcinogenesis and stroma formation (2023) (1)
- A Multicenter, Validation Study of Cyst Fluid Analysis for MAB Das-1 for the Identification of High-Risk and Malignant Mucinous Cysts of the Pancreas (2017) (1)
- Abstract 1561: Evaluation of mesothelin BiTE® antibody constructs in models of pancreatic ductal adenocarcinoma (2019) (1)
- AB049. P-17. A phase II study of HDAC inhibition to sensitize to immunotherapy in advanced cholangiocarcinoma (2019) (1)
- A phase II trial of PD-1 inhibition with INCMGA00012 in patients with previously treated unresectable or metastatic adenosquamous pancreatic cancer. (2020) (1)
- Controlled delivery of cytokines for therapeutic cancer vaccination (1995) (1)
- Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1 (2019) (1)
- 711 Interim results of a phase 2 study of nivolumab and relatlimab in advanced mismatch repair deficient (dMMR) cancers resistant to prior PD-(L)1 inhibition (2022) (1)
- Inferring cellular and molecular processes in single-cell data with non-negative matrix factorization using Python, R, and GenePattern Notebook implementations of CoGAPS (2022) (1)
- RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. (2022) (1)
- Abstract 4693: Characterization of the tumor immune microenvironment in head and neck squamous cell carcinoma (SCCHN) (2018) (1)
- Phenotypic shifts of tumor associated macrophages and STAT3 mediated suppression of myeloid derived suppressor cells drive sensitization of HER2+ tumor immunity (2021) (1)
- Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumors (2021) (1)
- Feasibility of human gene therapy for renal cell carcinoma (1994) (1)
- AB113. P087. Single-cell sequencing defines genetic heterogeneity in pancreatic cancer precursor lesions (2018) (1)
- Pancreatic Ductal Adenocarcinoma Cortical Mechanics and Clinical Implications (2022) (1)
- Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways (2021) (1)
- Enhancement of an Allogeneic GM-CSF-Secreting Breast Cancer Vaccine by Immunomodulatory Doses of Cyclophosphamide and Doxorubicin (2003) (1)
- Abstract 2993: STING signaling in breast tumor microenvironment modulates immune checkpoint blockade efficacy in the neu-N mouse model of breast cancer (2017) (0)
- Abstract 4491: Association of intratumoral immunologic profile with overall survival in metastatic pancreatic cancer patients treated with combination immunotherapy with or without PD-1 blockade (2019) (0)
- Abstract PR10: Inhibition of MEK1/2 overcomes resistance to aPD-1 blockade in pancreatic ductal adenocarcinoma through modulation of NETosis in tumor-associated neutrophils (2022) (0)
- A phase I study of a mutant KRAS-targeted long peptide vaccine combined with ipilimumab/nivolumab in resected pancreatic cancer and MMR-proficient metastatic colorectal cancer. (2023) (0)
- Abstract 3935: AnnexinA2 regulates invasion and metastasis of pancreatic ductal adenocarcinoma through Semaphorin3d. (2013) (0)
- Nivolumab and a CCR2/CCR5 dual antagonist (BMS-813160) with or without GVAX for locally advanced pancreatic ductal adenocarcinomas: Results of phase I study. (2023) (0)
- Multi-Omics Analyses of Changes in the Tumor Microenvironment of Pancreatic Adenocarcinoma Following Neoadjuvant Treatment With Anti-PD-1 Antibody (2022) (0)
- Poster Viewing AbstractMultiplex Proximal Ligation Assay Identifies Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy (2016) (0)
- High concordance between DNA methylation of tumor suppressor loci in pancreatic cancer cell lines and their corresponding primary carcinoma (2000) (0)
- Abstract IA17: Fatal attraction: A new story featuring the immune system and pancreatic cancer. (2012) (0)
- A phase I study of a mutant KRAS-targeted long peptide vaccine in patients at high risk of developing pancreatic cancer. (2023) (0)
- Abstract P2-09-10: Epigenetic modulation—unlocking the potential of checkpoint inhibition in breast cancer (2019) (0)
- Vaccines and Their Role in CD8 T Cell-Mediated Antitumor Immunity (2016) (0)
- Abstract CN01-02: Tipping the balance from a procarcinogenic to an anticancer response to prevent pancreatic cancer (2013) (0)
- MOLECULAR CANCER THERAPEUTICS | LARGE MOLECULE THERAPEUTICS IgE-BasedTherapeuticCombinationEnhancesAntitumor Response in Preclinical Models of Pancreatic Cancer (2021) (0)
- Abstract 2130: Uncovering the spatial landscape of tumor-immune interactions using latent spaces from spatial transcriptomics (2022) (0)
- Abstract P3-01-01: A dual role of natural killer cells in breast cancer metastasis (2020) (0)
- IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer (2021) (0)
- Abstract PL04-03: Fatal Attraction: A new story featuring the immune system and pancreatic cancer (2015) (0)
- 207 A phase II study of intensified adjuvant therapy for resected pancreatic and other periampullary adenocarcinoma using radiation, 5Fu, leucovorin, dipyridamole and mitomycin-C (1999) (0)
- Analysis of immune checkpoint blockade biomarkers in elderly patients using large-scale cancer genomics data. (2021) (0)
- Abstract 5851: Cancer associated fibroblast crosstalk through VEGF increases tumor cell proliferation in human pancreatic ductal adenocarcinoma (2023) (0)
- Commentary (Laheru/Jaffee): Novel Vaccines for the Treatment of Gastrointestinal Cancers (2005) (0)
- SINGLE-CELL IMMUNE COMPETENCY SIGNATURES ASSOCIATE WITH SURVIVAL IN PHASE 2 GVAX AND CRS-207 RANDOMIZED STUDIES IN METASTATIC PANCREATIC CANCER PATIENTS (2020) (0)
- Abstract 4475: Site-specific profiling of TCR signaling (2020) (0)
- Dosimetric Correlations with Toxicity in the First Experience Validating Adjuvant Fractionated Stereotactic Body Radiation Therapy for Resectable Pancreatic Cancer (2015) (0)
- Clinical and molecular features of adenosquamous pancreatic cancer (ASQ): A distinct histological subtype. (2021) (0)
- Abstract CT005: T cell inflammation in the tumor microenvironment after agonist CD40 antibody: Clinical and translational results of a neoadjuvant clinical trial (2021) (0)
- Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report (2021) (0)
- Abstract 3154: Harnessing the adaptive potential of mechanoresponsive proteins to overwhelm pancreatic cancer dissemination and invasion (2018) (0)
- Abstract P5-04-06: Reprogramming the suppressive tumor microenvironment of breast cancer (2020) (0)
- Abstract LB-020: Neoantigen targeted vaccine converts pancreatic tumors into immune sensitive tumors (2019) (0)
- Abstract 3241: Single-cell RNA and TCR sequencing of tumor infiltrating lymphocytes identifies changes in pancreatic ductal adenocarcinomas following neoadjuvant treatment with combined anti-PD-1 blocking and anti-CD137 agonist therapy (2023) (0)
- CGH analysis of pancreatic adenocarcinoma cell lines (1997) (0)
- Abstract PO-111: A human single-cell RNA sequencing atlas of pancreatic ductal adenocarcinoma enables harmonized cell type calling and comprehensive analyses of potential intercellular signaling (2021) (0)
- Converging on a Cure: The Roads to Predictive Immunotherapy. (2023) (0)
- Erratum: Using quantitative seroproteomics to identify antibody biomarkers in pancreatic cancer (Cancer Immunology Research (2016) 4 (225-233)) (2016) (0)
- Abstract 3679: DNAJB1-PRKACA fusion in fibrolamellar hepatocellular carcinoma induces glutamine addiction and an immunosuppressive tumor microenvironment (2023) (0)
- AB095. P069. Identification of therapeutic genomic alterations by investigating cancer-related genes and microsatellite instability: road to precision medicine for pancreatic ductal adenocarcinoma (2018) (0)
- Three-dimensional genomic mapping of human pancreatic tissue reveals striking multifocality and genetic heterogeneity in precancerous lesions (2023) (0)
- Abstract LB-215: Concomitant targeting of tumor cells and induction of T cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. (2013) (0)
- Immunogenomic features of pathologic response to neoadjuvant immune checkpoint blockade in esophageal cancer. (2021) (0)
- Abstract 1323: 12-chemokine gene signature identifies major pathologic response in patients with hepatocellular carcinoma treated with neoadjuvant nivolumab and cabozantinib (2022) (0)
- HER-2 / neu Is a Tumor Rejection Target in Tolerized HER-2 / neu Transgenic Mice 1 (2000) (0)
- Abstract IA013: Age-related changes in pancreatic fibroblasts drive pancreatic cancer growth and progression (2023) (0)
- Abstract 3991: Profiling the immune tumor microenvironment in primary and recurrent epithelial ovarian cancer (2017) (0)
- Induction nivolumab or nivolumab/ipilimumab prior to concurrent chemoradiation plus nivolumab in patients with operable stage II/III esophageal/gastroesophageal junction cancer. (2018) (0)
- Carcinogenesisand Stem Cells in Gastrointestinal (2015) (0)
- Abstract PR-004: Systemic and intratumoral immune profiling in metastatic pancreatic cancer patients who received front-line FOLFIRINOX and were treated with combination immunotherapy with CTLA-4 blockade in the maintenance setting (2020) (0)
- Cancer Therapy : Preclinical Personalized Chemotherapy Pro fi ling Using Cancer Cell Lines from Selectable Mice (2013) (0)
- Abstract SY26-01: Vaccine induced immunity against cancer genes to prevent and treat pancreatic cancer (2014) (0)
- Ovarian Metastasis from Pancreatic Ductal Adenocarcinoma (2021) (0)
- Abstract 5167: Entinostat's modulation of myeloid derived suppressor cells through the STAT3-NFκB-AP-1 axis decreases suppressive signaling (2023) (0)
- Comprehensive DNA methylation analysis indicates that pancreatic intraepithelial neoplasia lesions are acinar-derived and epigenetically primed for carcinogenesis. (2023) (0)
- Strategies for Heating Up Cold Tumors to Boost Immunotherapies (2023) (0)
- Abstract LB-154: Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small cell lung carcinoma (NSCLC): A proposal for quantitative immune-related pathologic response criteria (irPRC) (2018) (0)
- Abstract PO-080: Patient-derived organoids and cancer associated fibroblasts as a co-culture model to explore cell type interactions in pancreatic cancer (2021) (0)
- Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1 (Journal for Immuno Therapy of Cancer (2019) 7 (40) DOI: 10.1186/s40425-018-0492-x) (2019) (0)
- A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS) (2020) (0)
- Abstract 489: Prevention of pancreatic intra-epithelial neoplasm progression by a Listeria monocytogenes vaccine targeting mutated Kras, an early genetic event in pancreatic tumor development. (2013) (0)
- Abstract 1555: Single cell level treatment-specific characterization of HER2+ breast cancers treated with immune checkpoint inhibitors and entinostat (2020) (0)
- Abstract 5670: Machine learning methods to identify salient genomic predictors of clinical responses to immune checkpoint inhibitor therapy (2020) (0)
- Abstract 2867: TH17 cells promote early pancreatic tumorigenesis. (2013) (0)
- Translational Cancer Research Priorities and the Role of Molecular Imaging (2022) (0)
- Abstract LB197: A pooled mutant KRAS peptide vaccine activates polyfunctional T cell responses in patients with resected pancreatic cancer (2023) (0)
- Contents Vol. 118, 2007 (2007) (0)
- Recombinant Vaccine Strategies for Breast Cancer Prevention (1997) (0)
- Achieving the Goals of the Cancer Moonshot Requires Progress against All Cancers. (2023) (0)
- Abstract 4623: Transcriptional analysis of the functional differences between M1 and M2 macrophages to identify new targets for myeloid cell modulation in pancreatic tumors (2017) (0)
- Abstract 1695: Exploiting the pancreatic cancer mutome for immune interception (2017) (0)
- Abstract B52: A novel quantitative proteomics approach to identify proteins that elicit antibody responses in vaccinated pancreatic cancer patients. (2013) (0)
- Abstract 637: Spatial transcriptomics for FFPE characterizes the molecular and cellular architecture of malignant changes in pancreatic pre-malignant lesions (2022) (0)
- Association of low total lymphocyte count with overall and disease-free survival in patients with resected pancreatic adenocarcinoma receiving the GM-CSF secreting pancreatic tumor vaccine in combination with adjuvant chemoradiation. (2012) (0)
- Abstract 2728: Characterization of splicing-derived neoantigens using splicemutr shows their independence from TMB and potential as a biomarker for immunotherapy response (2022) (0)
- Abstract CT164: A Phase II clinical trial of GVAX pancreas vaccine (with Cyclophosphamide) in combination with Nivolumab and Stereotactic Body Radiation Therapy (SBRT) followed by definitive resection for patients with borderline resectable pancreatic adenocarcinoma (BR-PDAC) (2019) (0)
- Abstract 1970: Single cell proteomic quantification of T cell states using mass cytometry for applications in monitoring immune responses in cancer immunotherapy clinical trials (2022) (0)
- Abstract 3993: Programmed cell death ligand-1 (PD-L1) and CD8 expression profiling identifies an immunologic subtype of pancreatic ductal adenocarcinomas with favorable survival (2019) (0)
- Abstract 2968: TH17 cells in early pancreatic tumorigenesis (2012) (0)
- Can We Predict Mutant Neoepitopes in Human Cancers for Patient-Speci fi c Vaccine Therapy ? (2014) (0)
- An exploratory study of metformin (Met) with or without rapamycin (Rapa) as maintenance therapy after induction chemotherapy in patients (Pts) with metastatic pancreatic adenocarcinoma (PDA). (2020) (0)
- A phase 2b, randomized, controlled, multicenter, open-label study of the efficacy and immune response of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study) (2015) (0)
- Gene-Modified Tumor-Cell Vaccines (2004) (0)
- Solid Organ Transplantation Is Associated with an Increased Rate of Mismatch Repair Deficiency and PIK3CA Mutations in Colorectal Cancer (2022) (0)
- Recruitment of High Avidity Antigen Specific T Cells With T Regulatory Cell Modulation (2005) (0)
- Abstract 1923: Regulatory T-cell subsets suppress high avidity CD8 T-cell activation and trafficking (2010) (0)
- A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint (2021) (0)
- Immunotherapeutics Including Vaccines, Bispecifics, CAR-T, and Checkpoint Inhibitors (2019) (0)
- Abstract 1529: STAT3 mediates epigenetic regulation of MDSCs in tumors (2019) (0)
- Abstract IA01: Turning the heat up on pancreatic cancer: Lessons on overcoming a “cold” immunologic microenvironment (2020) (0)
- 104: Granulocyte macrophage colony stimulating factor (GM-CSF) transfected vaccine for esophageal cancer causes regression of subcutaneous implants in rats (2007) (0)
- Organoid Personalized Therapeutics and the Pancreatic Adenocarcinoma Signature Stratification for treatment (PASS) – 01 trial (2020) (0)
- Dissecting the Mechanism of T Cell Tolerance for More Effective Breast Cancer Vaccine Development (2004) (0)
- Direct activation of STING in the tumor microenvironment partially overcomes immune tolerance in neu-N transgenic mice (2015) (0)
- 989 PREDISPOSING FACTORS FOR POOR CLINICAL OUTCOME OF HEPATITIS B VIRUS ASSOCIATED HEPATOCELLULAR CARCINOMA FOLLOWING CURATIVE RESECTION: FOCUSED ON THE GENOMIC CHANGES IN HEPATITIS B VIRUS (2011) (0)
- Abstract 2768: Non-invasive detection of pancreatic adenocarcinoma using Ga-68 labelled epha2 targeting peptide (2023) (0)
- Abstract 2372: Mechanisms of microRNA-21 dysregulation in pancreatic ductal adenocarcinoma (PDAC) (2021) (0)
- Abstract 3638: Age-related changes in pancreatic fibroblasts promote growth and progression of pancreatic cancer (2022) (0)
- Abstract P2-04-11: Promotion of immunogenicity using epigenetic modulation and immune checkpoint inhibition in mouse models of breast cancer (2017) (0)
- Abstract 3256: Entinostat enhances the efficacy of checkpoint inhibition in breast-to-lung metastases and is associated with alterations in the phenotype and function of myeloid cell populations (2023) (0)
- Abstract 1686: Epigenetic modulation of the tumor microenvironment enhances vaccine induced T cell responses in a murine model of pancreatic cancer (2017) (0)
- Abstract IA001: Intercepting pancreatic cancer development with oncogene targeted immunotherapy (2022) (0)
- Abstract B54: Low avidity tumor-specific CD8+ T cells are regulated by increased expression of proapoptotic proteins in tolerant mice. (2013) (0)
- Why is it so difficult to enroll patients in clinical trials (2014) (0)
- Generation of Renal Cell Carcinoma-specific CD4 + /CD8 + T Cells Restricted by an HLA-39 from a RCC Patient Vaccinated with GM-CSF Gene-Transduced Tumor Cells (2003) (0)
- Abstract 1746: Epigenetic modulation of the tumor microenvironment enhances immune checkpoint efficacy in a murine model of pancreatic cancer (2018) (0)
- Abstract 2873: Evolution of immune cell composition and functionality as pancreatic intraepithelial neoplasia progresses to pancreatic ductal adenocarcinoma (2023) (0)
- Impaired Ca++ mobilization in rituximab-resistant cells is associated with changes in the structure of CD20 antigen and downregulation of Bax/Bak pro-apoptotic proteins (2006) (0)
- AB095. P069. Identification of therapeutic genomic alterations by investigating cancer-related genes and microsatellite instability: road to precision medicine for pancreatic ductal adenocarcinoma (2018) (0)
- Stromal changes in the aged lung induce an emergence from melanoma dormancy (2022) (0)
- Abstract PR-004: Systemic and intratumoral immune profiling in metastatic pancreatic cancer patients who received front-line FOLFIRINOX and were treated with combination immunotherapy with CTLA-4 blockade in the maintenance setting (2020) (0)
- Abstract 3398: PTPN22 is a systemic target for augmenting antitumor immunity (2020) (0)
- Abstract OT-13-08: A remote-directed “virtual” clinical trial in metastatic breast cancer to determine feasibility of evaluating patient response to immunotherapy using spliceosome mutational markers (SF3B1): The PRISMM trial (NCT04447651) (2021) (0)
- The monoclonal antibody 7.16.4 sequenced with cyclophosphamide-modulated vaccination maximizes tumor immunity and tumor-free survival in tumor-bearing tolerant neu-N mice (2008) (0)
- Epigenetic priming prior to pembrolizumab in microsatellite-stable (MSS) advanced colorectal cancer. (2016) (0)
- A phase IIb, randomized, controlled, multicenter, open-label study of the efficacy and immune response of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). (2014) (0)
- Manipulating Immunological Checkpoints to Maximize Antitumor Immunity (2006) (0)
- Abstract B68: NF-kB p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma (2020) (0)
- Serum Protein Expression and Associations With Conversion to Resectable Status Following Chemotherapy and Stereotactic Body Radiation Therapy in Locally Advanced Pancreatic Adenocarcinoma (2016) (0)
- Abstract 4979: Novel miRNA regulation in an early progression model of pancreatic ductal adenocarcinoma (2018) (0)
- 377 GENOMIC CHANGES IN HEPATITIS B VIRUS ASSOCIATED WITH THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA: A COHORT STUDY IN PATIENTS WITH CHRONIC HEPATITIS B OF GENOTYPE C2 (2011) (0)
- Abstract 4965: Entinostat transforms the suppressive tumor microenvironment of breast cancer and promotes survival and anti-responses when combined with checkpoint inhibition (2018) (0)
- Abstract 3778: Combination immunotherapy intercepts murine pancreatic cancer progression (2018) (0)
- Methods for retrovirus-mediated gene transfer to tumor cells. (1997) (0)
- Characterization of Mesothelin-Specific T Cell Responses in Healthy Individuals (2005) (0)
- 177 Recruitment of high avidity antigen-specific T cells in pancreatic cancer patients (2009) (0)
- Multi-targeted therapy with a HER-2/neu-specific vaccine and a VEGF-R2 inhibitor enhances anti-tumor immunity (2006) (0)
- Analysis of Immune Response Induced by Tumors Engineered to Secrete Cytokines (1995) (0)
- Abstract 5076: Combination PancVAX neo-epitope vaccine with anti-CTLA-4 and anti-PD-1 antibodies enhances infiltration of cytotoxic T cells and mitigates T cell exhaustion in a murine model of pancreatic ductal adenocarcinoma (2023) (0)
- Application of Apoptogenic Pretreatment to Enhance Anti-tumor Immunity of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)-secreting CT26 Tumor Cells (2005) (0)
- Abstract 2481: Imaging pancreatic ductal adenocarcinoma using an EphA2 receptor tyrosine kinase binding 68Ga-labeled peptide radiotracer (2022) (0)
- Inflammatory Signaling in Pancreatic Cancer Transfers Between a Single-cell RNA Sequencing Atlas and Co-Culture (2022) (0)
- Concomitant Targeting of TumorCells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab- Resistant Breast Cancer (2012) (0)
- Abstract 2352: Epigenetic modulation— unlocking the potential of checkpoint inhibition in advanced breast cancer (2019) (0)
- Abstract IA26: Combinatorial immunotherapies with the potential to reverse the carcinogenesis process (2016) (0)
- Abstract 4297: mAbXcite: A novel immunotherapy platform that initiates a robust anti-cancer immune response by recruiting and activating neutrophils (2015) (0)
- Poly (ADP Ribose) Polymerase Inhibition with ABT-888 Alone and in Combination with Gemcitabine Enhances Radiosensitization of Pancreatic Cancer Cells (2010) (0)
- Dual immune checkpoint blockade in advanced well-differentiated neuroendocrine tumors, a phase II clinical trial. (2021) (0)
- Immune Response Players in the Vaccine-Induced Antitumor Nondominant CD8 T Cells Are Active (2011) (0)
- Abstract 3413: Transfer learning identifies common cellular determinants of immune checkpoint inhibitor response between preclinical tumor models and patients (2020) (0)
- Abstract 5027: Sequencing the tumor microenvironment and myeloid derived suppressor cells to understand response to immunotherapy in primary HER2 positive breast cancer (2019) (0)
- Targeting Early Stage DCIS Breast Cancer Directly in the Ducts with Intraductal Chemotherapy (2006) (0)
- Abstract IA10: Tipping the balance from a procarcinogenic to anticancer response in pancreatic cancer. (2013) (0)
- Intensified adjuvant therapy for periampullary (pancreatic, nonpancreatic) adenocarcinoma using irradiation, 5FU, mitomycin C, leucovorin and dipyridamole (J9625)-update results (2000) (0)
- Abstract #713: Characterization of a new candidate target for pancreatic cancer immunotherapy: Tyrosine phosphorylation regulates cell surface translocation of Annexin A2 and contributes to pancreatic cancer invasion (2009) (0)
- The development and characterization of a natural killer cell-resistant human renal cell carcinoma cell line. (1992) (0)
- 318 Early Vaccination Targeting Mutated KRAS As An Antigen Expressed By Panins Delays Progression to Pancreatic Tumors in a Mouse Model (2008) (0)
- Abstract B59: Regulation of tumor-specific CD8 T cells via interactions between galectin-3 and surface glycoproteins. (2013) (0)
- Characterization of the immune tumor microenvironment of HER2-positive breast cancer following treatment with entinostat and immune checkpoint inhibition. (2020) (0)
- Abstract 480: Novel miRNA regulation in an early progression model of PDA (2017) (0)
- Long term survivors and immune biomarker analysis of Phase IIa, randomized study of GVAX pancreas and crs-207 immunotherapy in patients with metastatic pancreatic cancer (2015) (0)
- Abstract IA013: Intercepting pancreatic cancer development with mutant KRAS-targeted immunotherapy (2022) (0)
- Abstract 2270: Combination of CXCR4 antagonist and anti-PD1 therapy results in significant mobilization and increased infiltration of myeloid cells into the metastatic liver microenvironment of PDAC (2023) (0)
- Abstract B27: IgE-independent hypersensitvity reactions are associated with prolonged survival in advanced pancreatic cancer patients receiving a GM-CSF cell-based vaccine plus cyclophosphamide (Cy) and cetuximab. (2013) (0)
- Complex karyotypes consistently found in most adenocarcinomas of the pancreas (1997) (0)
- Conformation Dependent and Binds to the II-Restricted Tumor Antigen Is An Immunodominant MHC Class (2001) (0)
- Abstract 455: Pro-apoptotic proteins affect survival of tumor-specific low avidity CD8 + T cells in tolerant mice. (2013) (0)
- Evidence for gene amplification in pancreatic adenocarcinoma using fish and characterization of marker chromosomes by chromosome microdissection (1997) (0)
- 944 Fibroblasts as paracrine targets of the oncometabolite D-2-HG in the IDH1-mutant cholangiocarcinoma tumor microenvironment (2021) (0)
- Novel vaccines for the treatment of gastrointestinal cancers: Commentary (2005) (0)
- Abstract IA16: Tipping the balance from a procarcinogenic to an antitumor microenvironment in pancreatic cancers (2016) (0)
- Abstract 1480: miR-21 as a post-transcriptional regulator of pancreatic ductal adenocarcinoma (PDAC) tumorigenesis (2022) (0)
- Abstract C036: Cancer associated fibroblasts are regulators of the tumor microenvironment in human pancreatic ductal adenocarcinoma (2022) (0)
- Abstract 4697: Expression variation analysis for tumor heterogeneity in single-cell RNA-sequencing data (2019) (0)
- Abstract P1-08-01: Combination checkpoint inhibition and epigenetic modulation promotes tumor suppression and improves survival in Her2+ models of breast cancer (2018) (0)
- Immune cells track hard-to-target brain tumours (2018) (0)
- Immunotherapy for Pancreatic Cancer (2018) (0)
- Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence (2023) (0)
- Abstract 581: Determining the influence of galectin-3 binding properties on its suppression of tumor antigen-specific CD8+T cells (2019) (0)
- Abstract CT036: Safety and immunogenicity of a first-in-human mutant KRAS long peptide vaccine combined with ipilimumab/nivolumab in resected pancreatic cancer: Preliminary analysis from a phase I study (2023) (0)
- Development of mutome-specific personalized vaccines for pancreatic cancer (2013) (0)
- Identification and characterization of mMesothelin epitopes following a combinatorial vaccine approach (2008) (0)
- Development of Vaccine Therapy for Pancreas Cancer (2008) (0)
- A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy (2022) (0)
- Abstract 3820: Spatial transcriptomics of advanced hepatocellular carcinomas distinguishes intercellular interactions in responders and non-responders to cabozantinib and nivolumab neoadjuvant therapy (2022) (0)
This paper list is powered by the following services:
Other Resources About Elizabeth Jaffee
What Schools Are Affiliated With Elizabeth Jaffee?
Elizabeth Jaffee is affiliated with the following schools:
